2019/06/19 by Katharine J. Bar, Ernesto Coronado, Tiffany Hensley‐McBain +19
Immunology and Microbiology · Medicine · #HIV Research and Treatment #HIV/AIDS Research and Interventions #HIV/AIDS drug development and treatment
paper · pdf · doi:10.1128/jvi.00372-19
testing of novel treatments. However, many of the currently available SHIVs have distinct drawbacks and are unable to fully reflect the features characteristic of primary SIV and HIV strains. Here, we utilize rhesus macaques to define the immunopathogenesis of the recently developed SHIV.CH505, which was designed without many of the limitations of previous SHIVs. We observed that infection with SHIV.CH505 leads to peripheral viral kinetics and mucosal immunopathogenesis comparable with those caused by pathogenic SIV and HIV. Overall, these data provide evidence of the value of SHIV.CH505 as an effective model of SIV/HIV infection and an important tool that can be used in future studies, including preclinical testing of new therapies or prevention strategies.